跳至主要内容
临床试验/NCT00786916
NCT00786916已完成4 期

Efficacy of Intravenous Lidocaine at Alleviating Pain Associated With Propofol Infusion in Pediatric Patients Undergoing Procedural Sedation

Akron Children's Hospital1 个研究点 分布在 1 个国家目标入组 109 人开始时间: 2008年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
109
试验地点
1
主要终点
Maximal Pain/Discomfort

研究概览

简要总结

This protocol describes a double-blind, placebo-controlled trial intended to demonstrate the effectiveness of lidocaine at reducing pain associated wiht propofol infusion for short-term deep sedation in children. Patients will be randomized to receive either placebo (saline) or one of two dosing regimens of IV lidocaine prior to initiating propofol infusion. The efficacy of the differing lidocaine doses will be compared to determine the minimum dose required to safely achieve alleviation of pain. We hypothesize that premedicating with lidocaine will significantly decrease pain experienced by pediatric patients receiving propofol for outpatient sedation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
2 Years 至 7 Years(Child)
性别
All
接受健康志愿者

入选标准

  • scheduled for painless diagnostic procedures
  • are ASA I or ASA II

排除标准

  • have an indwelling central venous catheter
  • have received an analgesic or sedative medication in the previous four hours prior to enrollment
  • have an underlying chronic disorder that would impact on their ability to express distress when in painful or otherwise anxiety-provoking situations
  • known hypersensitivity to lidocaine or any component of the formulation
  • hypersensitivity to another local anesthetic of the amide type
  • Adam-Stokes syndrome
  • severe degrees of SA, AV, or intraventricular heart block
  • allergy to corn-related products
  • contraindication to propofol

研究组 & 干预措施

Group A

Placebo Comparator

Saline

干预措施: normal saline (Drug)

Group B

Active Comparator

Lidocaine 0.25 mg/kg

干预措施: lidocaine (Drug)

Group C

Active Comparator

Lidocaine 0.5 mg/kg

干预措施: lidocaine (Drug)

结局指标

主要结局

Maximal Pain/Discomfort

时间窗: during initial 3 minute propofol infusion

FLACC (Face, Legs, Activity, Cry, Consolability) Pain assessment scale was administered by a trained observer. The patient's parent documented maximum distress using a 100-mm visual analog scale where "0" represented "no pain" and 100 (the furthest point to the left) represented the worst pain ever.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Michael D. Reed

Pharm.D.

Akron Children's Hospital

研究点 (1)

Loading locations...

相似试验